Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
25 hedge funds and large institutions have $16.1M invested in Elevation Oncology in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
4.8% less ownership
Funds ownership: 66.11% → 61.31% (-4.8%)
7% less funds holding
Funds holding: 27 → 25 (-2)
25% less capital invested
Capital invested by funds: $21.5M → $16.1M (-$5.38M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$81K |
| 2 |
Renaissance Technologies
New York
|
+$38.1K |
| 3 |
AC
Annandale Capital
Dallas,
Texas
|
+$37.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$213 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$1.22M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$250K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$85.4K |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$39.2K |
| 5 |
VF
Virtu Financial
New York
|
-$31K |
ELEV Hedge Fund Activity: Q3 2022 in Review
25 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q3 2022, worth a combined $16.1M — down 25% from $21.5M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ELEV and 2 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Geode Capital Management, adding an estimated $81K. The largest seller was Boxer Capital, exiting entirely with an estimated $1.22M sold.
- 25 institutional investors held Elevation Oncology (ELEV) as of Q3 2022, down from 27 in Q2 2022.
- Funds reported $16.1M of Elevation Oncology stock for Q3 2022, down 25% quarter-over-quarter.
- 2 funds opened new Elevation Oncology positions in Q3 2022 and 4 closed out, a net change of -2 holders.
- The largest Elevation Oncology buyer in Q3 2022 was Geode Capital Management, an estimated $81K added.
- The largest Elevation Oncology seller in Q3 2022 was Boxer Capital, an estimated $1.22M sold.
Based on aggregated 13F filings for Q3 2022.